Preliminary study findings show ACE inhibitors increased the risk of breast cancer recurrence in patients, but beta blockers seemed to reduce the risk. When combining the two types of drugs, the beta blockers seemed to reduce the risk linked with ACE inhibitors.

Victrelis (boceprevir) has been approved to treat certain adults with chronic hepatitis C, including those who have not been treated with drug therapy for their hepatitis C, and may be used in combination with peginterferon alfa and ribavirin.